General practices (GPs) are paid for providing essential services to all their patients via global sum payments, which are weighted to take patient needs into account. Therefore, there are no dedicated GP payments for providing services to non-United Kingdom or non-registered UK citizens, and the Department does not hold data on GP patient lists by nationality.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4117", "label" : {"_value" : "Biography information for Andrea Leadsom"} } , "answeringMemberConstituency" : {"_value" : "South Northamptonshire"} , "answeringMemberPrinted" : {"_value" : "Andrea Leadsom"} , "dateOfAnswer" : {"_value" : "2024-04-30", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1713829/answer/previousversion/31584", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4117", "label" : {"_value" : "Biography information for Andrea Leadsom"} } , "answeringMemberConstituency" : {"_value" : "South Northamptonshire"} , "answeringMemberPrinted" : {"_value" : "Andrea Leadsom"} } , "questionFirstAnswered" : [{"_value" : "2024-04-30T21:20:59.253Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "General Practitioners: Finance"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the cost to NHS England has been of reimbursing GP practices for providing services to (a) non-UK and (b) non-registered UK citizens in each of the last three years for which information is available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"} } , "tablingMemberConstituency" : {"_value" : "Christchurch"} , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"} ], "uin" : "23670"} , {"_about" : "http://data.parliament.uk/resources/1181941", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1181941/answer", "answerText" : {"_value" : "
On 11 November 2019, the National Institute for Health and Care Excellence (NICE) published clinical guidelines on the prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy. The guidelines recommend that cannabis-based medicinal products are not offered to manage chronic pain in adults and that cannabidiol only be offered as part of a clinical trial. NICE recognises the lack of evidence to support the use of these medicines and recommends that further research is carried out on the clinical and cost effectiveness as an add-on treatment for persistent treatment-resistant neuropathic pain and chronic pain in adults, children and young people. Further information and the clinical guidelines are available on the NICE website at the following link:<\/p>